檢索結果 - David E. Gerber

Refine Results
  1. 1
    EGFR inhibition in the treatment of non‐small cell lung cancer

    EGFR inhibition in the treatment of non‐small cell lung cancer 由 David E. Gerber

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Targeting the PI3K Pathway for Cancer Therapy

    Targeting the PI3K Pathway for Cancer Therapy 由 Navid Sadeghi, David E. Gerber

    出版 2012
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

    Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment 由 Lorraine Pelosof, David E. Gerber

    出版 2010
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    ALK alterations and inhibition in lung cancer

    ALK alterations and inhibition in lung cancer 由 Tri Le, David E. Gerber

    出版 2016
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

    Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? 由 Tri Le, David E. Gerber

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review

    Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review 由 Shaheen Khan, David E. Gerber

    出版 2019
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    AXL Inhibitors: Status of Clinical Development

    AXL Inhibitors: Status of Clinical Development 由 Sheena Bhalla, David E. Gerber

    出版 2023
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea

    Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea 由 David E. Gerber, Joan H. Schiller

    出版 2013
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

    ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time 由 David E. Gerber, John D. Minna

    出版 2010
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  10. 10
    ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer

    ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer 由 David E. Gerber, GR Oxnard, Ramaswamy Govindan

    出版 2015
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  11. 11
    Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

    Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy 由 Sawsan Rashdan, John D. Minna, David E. Gerber

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

    Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis 由 Mitchell S. von Itzstein, Shaheen Khan, David E. Gerber

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  13. 13
    Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

    Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity? 由 Jeffrey T. Yorio, Yang Xie, Jingsheng Yan, David E. Gerber

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer

    Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer 由 Caitlin C. Murphy, David E. Gerber, Sandi L. Pruitt

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

    BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer 由 Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber, Rolf A. Brekken

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Prevalence of Autoimmune Disease Among Patients With Lung Cancer

    Prevalence of Autoimmune Disease Among Patients With Lung Cancer 由 Saad A. Khan, Sandi L. Pruitt, Lei Xuan, David E. Gerber

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

    Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors 由 David Hsiehchen, Mary Katherine Watters, Rong Lü, Yang Xie, David E. Gerber

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1

    The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1 由 David E. Gerber, Stuart A. Grossman, Michel Zeltzman, Michele A. Parisi, Lawrence Kleinberg

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition

    Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition 由 Pavel A. Levin, Melissa Mayer, Sharon Hoskin, Joseph Sailors, Dwight Oliver, David E. Gerber

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials

    Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials 由 David E. Gerber, Andrew L. Laccetti, Lei Xuan, Ethan A. Halm, Sandi L. Pruitt

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: